RE:RE:RE:RE:ONCY pelareorep + CD3 bispecific antibody true-killer comboIn November 2022, Pfizer announced elranatamab received Breakthrough Therapy Designation from the Food and Drug Administration (FDA) for the treatment of RRMM.
Elranatamab has also been granted Orphan Drug Designation by the FDA and the European Medicines Agency (EMA) for the treatment of MM. The FDA and EMA have granted elranatamab Fast Track Designation and the PRIME scheme, respectively, for the treatment of patients with RRMM.
“Discovered and developed at Pfizer, elranatamab is just one example of our focus on investing in breakthrough science. We're applying our expertise in hematology developed over a decade to advance elranatamab as an innovative treatment for multiple myeloma,” said Chris Boshoff, M.D., Ph.D., Chief Development Officer, Oncology and Rare Disease, Pfizer Global Product Development.